Therapeutic Application of Empagliflozin, Sitagliptin, and Metformin for Advancing Overall Wellness in T2D: Evidence Review for Practitioners in 2025 Dr. Manoj Chadha19 Feb 2026 10:35 AM ISTHyperglycemia in T2D plays a pivotal role in diabetic microvascular complications; however, reducing HbA1c offers only modest benefit in mitigating...
MI Accelerates Transition of Obese Prediabetes Patients to Diabetes, Semaglutide Prevents: Study Medha Baranwal19 Feb 2026 10:00 AM ISTDenmark: A study published in Cardiovascular Diabetology has found that patients with overweight or obesity who have prediabetes after a myocardial...
Long term exposure to transportation noise especially from Railways May Raise Diabetes Risk, Study of Nearly 1 Million Finds Medha Baranwal18 Feb 2026 11:30 AM ISTUSA: Long-term exposure to transportation noise-especially from railways-may increase the risk of developing type 2 diabetes, a large retrospective...
Real-World Study Shows Sustained Glycaemic Benefit and Acceptable Safety of Imeglimin in Type 2 Diabetes Aashi verma17 Feb 2026 12:45 PM ISTJapan: A recent real-world study finds that imeglimin transforms Type 2 Diabetes (T2D) care by maintaining a 0.8% mean reduction in Glycated...
Natco Pharma's Generic Semaglutide to Hit Indian Market in March Parthika Patel14 Feb 2026 9:26 PM ISTNew Delhi: Natco Pharma Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market...
Use of Diabetes-Specific Protein Supplement Improves Glycemic Control in Type 2 Diabetes: Study Medha Baranwal14 Feb 2026 8:45 AM ISTIndia: Researchers have discovered in a new study that using a diabetes-specific protein supplement as a partial breakfast replacement improves blood...
Low-Impact Leg Exercises Linked to 35 Percent Lower Diabetes Risk: Indian Researchers Find Medha Baranwal13 Feb 2026 9:00 AM ISTIndia: A new review published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews suggests that simple, non-weight-bearing...
Once-Monthly GLP-1 Injection Shows Significant Weight Loss Without Plateau in non diabetics in Phase 2 trial Dr. Kamal Kant Kohli13 Feb 2026 8:00 AM ISTPfizer reported that its ultra-long-acting, once-monthly GLP-1 injectable achieved up to 12.3% placebo-adjusted weight loss by week 28, with no...
HbA1c May Not Reliably Reflect Blood Sugar Levels in Many Indians: Lancet Viewpoint Anshika Mishra13 Feb 2026 8:00 AM ISTA new evidence-based viewpoint published in The Lancet Regional Health: Southeast Asia has raised concerns about the reliability of the widely used...
